Article Text

PDF

Managing severe lower limb spasticity in multiple sclerosis: does intrathecal phenol have a role?
  1. L Jarrett1,
  2. P Nandi1,
  3. A J Thompson1,2
  1. 1National Hospital for Neurology and Neurosurgery, University College London Hospitals, London, UK
  2. 2Institute of Neurology, University College London, London, UK
  1. Correspondence to:
 Professor A J Thompson, Institute of Neurology, Queen Square, London WC1 N 3BG, UK;
 a.thompson{at}ion.ucl.ac.uk

Abstract

Objective: Established treatment options for managing severe lower limb spasticity and associated pain are of limited value in people with advanced multiple sclerosis (MS). This has resulted in a resurgence of the use of lumbar intrathecal phenol injection (IP). The aim of this study was to investigate the authors' experience with IP.

Methods: This observational study collected cross sectional data from patients with progressive MS who received IP for severe lower limb spasticity. Data from 25 patients were collected prospectively before and after treatment. In 15 cases the data related to the first treatment and in 10 to serial injections. Outcome measures collected included the Ashworth scale, a spasm frequency scale, a pain rating score, and the percentage achievement of practical goals.

Results: After injection, all patients demonstrated reduced lower limb tone bilaterally. After the initial injection there was significant improvement on the targeted as compared with the non-targeted side (Wilcoxon rank p=0.003), while no difference in the degree of improvement between the targeted and non-targeted side was seen after serial injections (Wilcoxon rank p=0.731). Twenty four patients were easier to position and 21 had a reduction in their spasm frequency and intensity. Eleven patients with pain reported benefit. Carers found washing and dressing easier in 16 patients and improved safety when using the hoist in 10. Six patients had recurrence of skin breakdown and five patients reported transient adverse changes in their bowel function.

Conclusions: IP can reduce lower limb tone bilaterally after both initial and serial injections. This is most noticeable on the targeted side after initial injection. IP can reduce spasms and pain, leading to improvements in care and overall comfort. IP is an effective treatment option in the management of severe spasticity. Documented selection criteria are essential.

  • lower limb spasticity
  • multiple sclerosis
  • intrathecal phenol
  • MS, multiple sclerosis
  • IP, intrathecal phenol

Statistics from Altmetric.com

Footnotes

  • Competing interests: none declared.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.